Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.
- First patient dosed in Phase IIa PROTECT-MI trial
- Multiple Australian hospital sites activated for recruitment
- Preclinical studies show anti-tumour and cardioprotective potential
- US patent allowance received, grant expected soon
- Cash balance strengthened to AU$8.39 million at quarter end
Phase IIa Trial Advances with First Patient Dosed
Nyrada (ASX:NYR) has reached a key milestone in its Xolatryp® program by dosing the first patient in its Phase IIa PROTECT-MI clinical trial. The study is designed to evaluate the safety and preliminary efficacy of Xolatryp in reducing cardiac tissue damage following heart attacks, specifically in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI.
Recruitment is underway at Nepean Hospital in New South Wales, which was activated early in the quarter, with Sir Charles Gairdner Hospital in Western Australia coming online shortly after quarter-end. The company is progressing approvals at five additional Australian sites and exploring expansion into New Zealand, maintaining flexibility to allocate resources where recruitment is strongest. Completion of patient dosing is expected by mid-2027, with top-line results anticipated approximately three months thereafter.
Promising Preclinical Data in Oncology and Cardioprotection
Alongside clinical progress, Nyrada announced encouraging results from two preclinical studies. Xolatryp demonstrated significant anti-tumour activity in a liver cancer model, both as a standalone treatment and in combination with doxorubicin chemotherapy, with the combination showing the greatest tumour volume reduction and good tolerability.
A pilot cardioprotection study also showed that Xolatryp may mitigate doxorubicin-induced cardiomyopathy, a common chemotherapy side effect. Preliminary biomarker data revealed lower cardiac troponin I levels in treated subjects, suggesting reduced cardiac injury. This pilot confirmed the feasibility and tolerability of the subcutaneous dosing regimen and informs dose selection for a larger cardioprotection study currently underway, expected to report mid-first quarter 2027.
Strengthened Financial Position and US Patent Progress
Financially, Nyrada ended the quarter with AU$8.39 million in cash, up from AU$6.74 million three months earlier. The company benefited from a AU$2.46 million R&D tax rebate and AU$0.83 million from option exercises, offsetting operating outflows of approximately AU$1.66 million. Payments to related parties, including director fees and CEO salary, totalled AU$219,000 for the quarter.
On the intellectual property front, Nyrada received a formal Notice of Allowance from the US Patent Office for Xolatryp’s chemical structure and related analogues. The patent, stemming from a September 2024 filing, is expected to be granted imminently and will provide 20 years of protection in the US market, a critical step for commercialisation and regulatory strategy.
Regulatory Engagement and Next Steps
The company is preparing an Investigational New Drug (IND) application for submission to the US Food and Drug Administration, with a pre-IND meeting requested and the application planned before the end of 2026. This regulatory move could pave the way for future US clinical trials and market entry.
Investors will be watching recruitment progress across trial sites and the upcoming top-line Phase IIa data expected in 2027, which will be pivotal in assessing Xolatryp’s potential to reduce cardiac reperfusion injury. Meanwhile, the expanding preclinical oncology and cardioprotection programs suggest broader therapeutic opportunities beyond cardiac indications.
Bottom Line?
Nyrada’s advancement into Phase IIa dosing, coupled with US patent progress and solid cash reserves, places it on track for critical clinical readouts and regulatory milestones in 2027.
Questions in the middle?
- Will recruitment pace at activated sites meet timelines for mid-2027 trial completion?
- How will the FDA respond to Nyrada’s IND application and what impact might this have on US trial plans?
- Could Xolatryp’s emerging oncology and cardioprotection data expand its clinical development scope?